XML 35 R24.htm IDEA: XBRL DOCUMENT v3.25.3

REVENUES (Tables)

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

Summary of Total Revenues

The following table summarizes our Total revenues:

						Three Months Ended September 30, 2025																								Three Months Ended September 30, 2024
(in millions)						U.S.						Europe						Rest of World						Total						U.S.						Europe						Rest of World						Total
Product sales:
HIV
Biktarvy						$	2,940					$	427					$	320					$	3,686					$	2,826					$	375					$	272					$	3,472
Descovy						652						23						25						701						534						24						28						586
Genvoya						323						34						19						377						384						44						21						449
Odefsey						206						61						10						277						248						69						9						326
Symtuza - Revenue share(1)						95						26						3						124						103						33						3						139
Other HIV(2)						82						22						9						112						65						26						9						100
Total HIV						4,299						592						386						5,277						4,161						570						342						5,073
Liver Disease
Sofosbuvir/Velpatasvir(3)						146						65						97						309						222						67						96						385
Vemlidy						136						12						132						280						126						11						95						232
Other Liver Disease(4)						132						81						17						231						45						54						17						116
Total Liver Disease						414						158						247						819						393						132						207						733
Veklury						140						43						93						277						393						81						219						692
Oncology
Cell Therapy
Tecartus						40						35						8						83						63						29						6						98
Yescarta						123						151						75						349						145						182						60						387
Total Cell Therapy						163						186						83						432						208						211						66						485
Trodelvy						221						89						47						357						226						80						26						332
Total Oncology						384						275						129						788						433						291						92						816
Other
AmBisome						2						69						52						123						6						71						52						130
Other(5)						34						7						20						61						47						8						16						71
Total Other						36						76						72						184						53						80						68						201
Total product sales						5,274						1,144						928						7,345						5,433						1,154						928						7,515
Royalty, contract and other revenues						7						411						5						424						17						13						1						30
Total revenues						$	5,281					$	1,555					$	933					$	7,769					$	5,450					$	1,167					$	929					$	7,545

						Nine Months Ended September 30, 2025																								Nine Months Ended September 30, 2024
(in millions)						U.S.						Europe						Rest of World						Total						U.S.						Europe						Rest of World						Total
Product sales:
HIV
Biktarvy						$	8,212					$	1,231					$	922					$	10,366					$	7,726					$	1,110					$	814					$	9,649
Descovy						1,791						67						81						1,939						1,339						75						82						1,496
Genvoya						950						114						54						1,118						1,088						138						66						1,292
Odefsey						642						184						30						857						705						217						30						952
Symtuza - Revenue share(1)						265						88						9						362						338						101						9						448
Other HIV(2)						198						85						28						310						190						96						36						322
Total HIV						12,059						1,769						1,124						14,952						11,386						1,737						1,038						14,160
Liver Disease
Sofosbuvir/Velpatasvir(3)						497						227						273						996						737						230						299						1,266
Vemlidy						358						36						389						783						338						33						328						699
Other Liver Disease(4)						307						233						53						593						134						148						55						337
Total Liver Disease						1,162						496						714						2,372						1,210						411						682						2,302
Veklury						390						84						225						700						784						204						473						1,461
Oncology
Cell Therapy
Tecartus						122						107						25						254						181						102						22						305
Yescarta						444						455						228						1,127						502						509						170						1,181
Total Cell Therapy						566						562						253						1,381						683						611						192						1,485
Trodelvy						626						259						128						1,013						655						217						88						960
Total Oncology						1,192						821						381						2,395						1,338						828						280						2,446
Other
AmBisome						15						201						175						391						37						210						176						424
Other(5)						125						23						55						204						203						26						52						281
Total Other						140						225						230						594						241						236						228						705
Total product sales						14,943						3,395						2,674						21,013						14,958						3,416						2,700						21,074
Royalty, contract and other revenues						57						433						16						505						66						43						2						111
Total revenues						$	15,000					$	3,828					$	2,690					$	21,518					$	15,024					$	3,459					$	2,703					$	21,185

_______________________________

(1)    Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen Ireland”).

(2)    Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada, Tybost and Yeztugo/Yeytuo.

(3)    Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).

(4)    Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi/Lyvdelzi, Sovaldi, Viread and Vosevi.

(5)    Includes Cayston, Jyseleca, Letairis and Zydelig.

Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods

The following table summarizes revenues recognized from performance obligations satisfied in prior years:

						Three Months Ended												Nine Months Ended
						September 30,												September 30,
(in millions)						2025						2024						2025						2024
Revenue share with Janssen Ireland and royalties for licenses of intellectual property						$	148					$	173					$	458					$	545
Changes in estimates(1)						$	497					$	146					$	837					$	388

_______________________________

(1)    Changes in estimates increased during the three and nine months ended September 30, 2025 primarily due to recognition of $400 million of previously constrained revenues from the sale of certain intellectual property.

Summary of Contract Balances

The following table summarizes our contract balances:

(in millions)						September 30, 2025						December 31, 2024
Contract assets(1)						$	695					$	277
Contract liabilities(2)						$	56					$	58

_______________________________

(1)    The increase in contract assets during the nine months ended September 30, 2025 primarily related to recognition of $400 million of previously constrained revenues from the sale of certain intellectual property.

(2)    Future revenues recognized from contract liabilities are not expected to be material in any one year.

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of expected timing for satisfying remaining performance obligation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(1)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration